Rima McLeod - Chicago IL, US Bo Shiun Lai - Chicago IL, US William Witola - Chicago IL, US Kamal El Bissati - Chicago IL, US Ernest Mui - Chicago IL, US Hong Moulton - Corvallis OR, US Jonathan B Rothbard - Menlo Park CA, US Jon D Moulton - Corvallis OR, US
International Classification:
C12N 15/113 C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of infections.
Apicomplexan Chorismate Synthase Sequences And An Inhibitor Of The Shikimate Pathway
Rima McLeod - Chicago IL, US Michael Kirisits - Chicago IL, US Craig Roberts - Kirklee, GB Doug Mack - Centennial CO, US Ernest Mui - Chicago IL, US John Barnwell - Stone Mountain GA, US John Dame - Gainesville FL, US Jane Carlton - Rockville MD, US Paul Bartlett - Oakland CA, US Suzanna Parle - Seattle WA, US
International Classification:
C12Q001/18 C07H021/04 C12N001/10
US Classification:
435/032000, 435/258100, 536/023200
Abstract:
This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.
Rima McLeod - Chicago IL, US Stephen Muench - Stockport, GB John Rafferty - Sheffield, GB Dennis Kyle - , US Ernest Mui - Chicago IL, US Michael Kirisits - Chicago IL, US Douglas Mack - Centennial CO, US Craig Roberts - Glasgow, GB Benjamin Samuel - Chicago IL, US Russell Lyons - , US Wilbur Milhous - Germantown MD, US Sean Prigge - Severna Park MD, US David Rice - Sheffield, GB
Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases.
Antimicrobial Agents, Diagnostic Reagents, And Vaccines Based On Unique Apicomplexan Parasite Components
Rima McLeod - Chicago IL, US Craig Roberts - Glasgow, GB Fiona Roberts - Glosgow, GB Jennifer Johnson - Stillwater MN, US Michael Kirisits - Chicago IL, US David Ferguson - Tackley Oxford, GB Russell Lyons - Glasgow, GB Ernest Mui - Chicago IL, US Doug Mack - Riverside IL, US Benjamin Samuel - Chicago IL, US Piotr Gornicki - Chicago IL, US Ellen Zuther - Berlin, DE
International Classification:
A61K048/00 A01N063/00 A01H005/00
US Classification:
424093200
Abstract:
This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.
Rima McLeod - Chicago IL, US Michael Kirisits - Ho Chi Minh City, VN Dennis Kyle - Lithia FL, US Douglas G. Mack - Centinnel CO, US Wilbur Milhous - Tampa FL, US Stephen Muench - Leeos, GB Ernest J. Mui - Chicago IL, US Sean Prigge - Severna Park MD, US John Rafferty - Sheffield, GB David Rice - Sheffield, GB Craig W. Roberts - Glasgow, GB Benjamin Samuel - Chicago IL, US
Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases.
Rima McLeod - Chicago IL, US Tze Guan Tan - Cambridge MA, US Jeffery L. Alexander - San Diego CA, US Hua Cong - Shandong, CN William H. Witola - Auburn AL, US Kamal El Bissati - Chicago IL, US Ernest J. Mui - Chicago IL, US Steven G. Reed - Bellevue WA, US
Assignee:
THE UNIVERSITY OF CHICAGO - Chicago IL PAXVAX, INC. - San Diego CA INFECTIOUS DISEASE RESEARCH INSTITUTE - Seattle WA
International Classification:
A61K 39/002
US Classification:
4241911
Abstract:
Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is
Antimicrobial Agents, Diagnostic Reagents, And Vaccines Based On Unique Apicomplexan Parasite Components
Rima L. McLeod - Chicago IL Craig W. Roberts - Glasgow, GB Fiona Roberts - Glasgow, GB Jennifer J. Johnson - Stillwater MN Michael Kirisits - Chicago IL David Ferguson - Tackley Oxford, GB Russell Lyons - Glasgow, GB Ernest Mui - Chicago IL Doug Mack - Riverside IL Benjamin Samuel - Chicago IL Piotr Gornicki - Chicago IL Ellen Zuther - Beuhy, DE
This invention relates uses of chorismate synthase, a component components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, in assays to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on chorismate synthase and its inhibitors.